Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Short form equity change report
Name of listed company: Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Place of stock listing: Shanghai Stock Exchange
Stock abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Stock Code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Information disclosure obligor: Hunan Fangsheng Xinyuan Health Industry Investment Co., Ltd
Domicile / mailing address: No. 299, Jiayun Road, Changsha high tech Development Zone
Nature of share change: increase in shares (acquisition of new shares issued by listed companies)
Acting in concert 1: Zhang Qinghua
Address / mailing address: Yuelu District, Changsha City, Hunan Province
Concerted action 2: duilong Deqing symbiosis Venture Capital Management Co., Ltd
Address / mailing address: No. 1177, management committee of Industrial Park, duilongdeqing District, Lhasa, Tibet Autonomous Region
Signed on: March 6, 2022
Statement of information disclosure obligor
1、 This report is prepared in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of the acquisition of listed companies, the standards for the contents and forms of information disclosure by companies offering securities to the public No. 15 – Report on changes in equity and other relevant laws, regulations and normative documents.
2、 In accordance with the provisions of the above laws and regulations, this report has fully disclosed the shares in which the information disclosure obligor has an interest in Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as ” Hunan Fangsheng Pharmaceutical Co.Ltd(603998) “).
As of the signing date of this report, except for the shareholding information disclosed in this report, the information disclosure obligor has not increased or reduced its shares in Hunan Fangsheng Pharmaceutical Co.Ltd(603998) in any other way.
3、 The information disclosure obligor has obtained necessary authorization and approval for signing this report, and its performance does not violate or conflict with any provision in the articles of association or internal rules of the information disclosure obligor.
4、 This equity change is based on the information stated in this report. Except for the information disclosure obligor and the person acting in concert, no other person has been entrusted or authorized to provide information not listed in this report and make any explanation or explanation to this report.
5、 The information disclosure obligor and its persons acting in concert promise that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal liabilities for its authenticity, accuracy and completeness. 6、 The new shares issued by the listed company need to be approved by the general meeting of Hunan Fangsheng Pharmaceutical Co.Ltd(603998) shareholders and the China Securities Regulatory Commission.
catalogue
interpretation…… five
Section I basic information of information disclosure obligor six
1、 Basic information of information disclosure obligors and persons acting in concert six
2、 Information disclosure of controlling shareholders and actual obligations of controlling shareholders seven
3、 Brief description of the main business and financial status of the information disclosure obligor in the last three years IV. administrative punishment of the information disclosure obligor in the last five years (except those obviously irrelevant to the securities market)
Criminal punishment, major civil litigation or arbitration involving economic disputes eleven
5、 Basic information of the directors and their main principals of the information disclosure obligor Vi. information disclosure obligor’s directors and their principal principals’ positions in other companies VII. Information disclosure obligors owning more than 5% shares of other listed companies at home and abroad 12 VIII. Information disclosure obligors’ changes in controlling shareholders and actual controllers in the past two years
Description of twelve
Section II purpose and decision-making procedure of this equity change thirteen
1、 Purpose of this equity change II. The information disclosure obligor will continue to increase the shares of the listed company or dispose of its existing shares in the next 12 months
Intention to own equity shares thirteen
3、 Relevant decision-making procedures performed by the information disclosure obligor for this equity change thirteen
Section III method of equity change fourteen
1、 Changes in equity this time fourteen
2、 The main contents of the conditional effective share subscription agreement fifteen
3、 Payment method and source of funds eighteen
4、 Equity restrictions on shares of listed companies held by information disclosure obligors eighteen
5、 Major transactions with listed companies in the most recent year and period and future cooperation with listed companies
Other arrangements between companies nineteen
Section IV trading of listed shares in the first six months twenty
Section V other major matters twenty-one
Section VI documents for future reference twenty-two
1、 Documents for future reference twenty-two
2、 Location for future reference twenty-two
Attached table: simplified equity change report twenty-nine
interpretation
In this report, unless otherwise specified, the following words have the following specific meanings:
Listed company, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) refers to Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Information disclosure obligor refers to Hunan Fangsheng Xinyuan Health Industry Investment Co., Ltd
Yuan production and investment
Through agreements and other arrangements, investors and other investors jointly expand the acts or facts that they can act in concert, which refers to the acts or facts that can control the number of voting rights of shares of a listed company
Kaishun investment refers to Hunan Kaishun Investment Consulting Co., Ltd
Symbiotic investment refers to duilong Deqing symbiotic Venture Capital Management Co., Ltd
Bisheng environmental protection refers to Hunan Bisheng environmental protection Co., Ltd
This offering and this non-public offering refer to Hunan Fangsheng Pharmaceutical Co.Ltd(603998) this non-public offering of shares to specific objects
Issue
This equity change refers to the planned subscription of Hunan Fangsheng Pharmaceutical Co.Ltd(603998) non-public offering of no more than 56962025 shares (including this number) by sgy industrial investment
The report and simplified equity refer to Hunan Fangsheng Pharmaceutical Co.Ltd(603998) simplified equity change report
Change report
Shares with conditional effect refers to the share subscription agreement with the effect of the conditional subscription agreement for Hunan Fangsheng Pharmaceutical Co.Ltd(603998) non public offering shares
CSRC refers to the China Securities Regulatory Commission
Shanghai stock exchange refers to Shanghai Stock Exchange
China Securities Depository and Clearing Corporation refers to the Shanghai Branch of China Securities Depository and Clearing Corporation Limited
Company Law refers to the company law of the people’s Republic of China
Securities Law refers to the securities law of the people’s Republic of China
The measures for the administration of acquisition refers to the measures for the administration of the acquisition of listed companies
Standard No. 15 refers to Standard No. 15 on the contents and forms of information disclosure by companies offering securities to the public – Report on changes in equity
Yuan and 10000 yuan refer to RMB yuan and 10000 yuan
Note: if there is any difference in the mantissa between the sum of some total figures and each detailed figure in this report, these differences are caused by rounding.
Basic information disclosure obligations
The information disclosure obligor of this equity change is SGD industrial investment.
1、 Basic information of information disclosure obligors and persons acting in concert
(I) basic information of information disclosure obligor
Enterprise name: Hunan Fangsheng Xinyuan Health Industry Investment Co., Ltd
Registered address: No. 310, third floor, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) scientific research building, No. 299, Jiayun Road, Changsha high tech Development Zone
Legal representative: Zhou Xiaoli
Registered capital: 100 million yuan
Unified social credit code 91430100ma7j311n0p
Date of establishment: March 3, 2022
Company type: limited liability company (invested or controlled by natural person)
Business scope: general investment activities with self owned funds. (independently carry out business activities not prohibited or restricted by laws and regulations, except for projects subject to approval according to law)
Long term operation
Mailing address: No. 310, third floor, Hunan Fangsheng Pharmaceutical Co.Ltd(603998) scientific research building, No. 299, Jiayun Road, high tech Development Zone, Changsha
Tel: 1587407
(II) basic information of persons acting in concert of information disclosure obligors
1. Acting in concert 1: Zhang Qinghua
Name: Zhang Qinghua
Gender male
Nationality China
ID number 43022119740827
Address: Yuelu District, Changsha City, Hunan Province
Mailing address: Yuelu District, Changsha City, Hunan Province
Have you obtained the right of abode in other countries or regions
2. Concerted action 2: symbiotic investment
Enterprise name: duilong Deqing symbiosis Venture Capital Management Co., Ltd
Registered at No. 1177, management committee of Industrial Park, duilongdeqing District, Lhasa, Tibet Autonomous Region
Legal representative: Li Lina
The registered capital is 6 million yuan
Unified social credit Code: 914 Zhang Xiaoquan Inc(301055) 49159318
Date of establishment: May 5, 2010
Company type: limited liability company (invested or controlled by natural person)
Venture capital management; Pharmaceutical industry investment (not directly engaged in the above business, mainly business scope). [for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments.]
Business term: May 5, 2010 to May 4, 2060
Mailing address: No. 1177, management committee of Industrial Park, duilongdeqing District, Lhasa, Tibet Autonomous Region
Tel.: 1730899
(III) description of the relationship between the information disclosure obligor and the person acting in concert
Xinyuan Industrial investment, the obligor of information disclosure, is an enterprise controlled by Zhang Qinghua. Symbiotic investment is the shareholding platform of middle and senior managers established before Hunan Fangsheng Pharmaceutical Co.Ltd(603998) listing. Zhang Qinghua indirectly controls symbiotic investment through Kaishun investment. Therefore, Zhang Qinghua and symbiosis investment are the concerted actors of Xinyuan Industrial investment.
2、 Information disclosure obligors’ equity structure, controlling shareholders and actual controllers
(I) equity structure of information disclosure obligor
As of the signing date of this report, the equity structure of the information disclosure obligor is shown in the figure below: Note: Zhang Qinghua and Zhou Xiaoli are husband and wife.
(II) information on controlling shareholders and actual controllers of information disclosure obligors
The controlling shareholder and actual controller of Xinyuan Industrial investment, the information disclosure obligor, is Zhang Qinghua.
Zhang Qinghua, male, born in 1974, Chinese nationality, without overseas residency, college degree, EMBA of Tsinghua University. He has successively served as business manager of Guangzhou Economic and Technological Development Zone pharmaceutical industry Co., Ltd., manager, general manager and chairman of the marketing department of Guangzhou ruiri Pharmaceutical Co., Ltd., general manager of Guangdong Ruixing Pharmaceutical Co., Ltd., chairman and general manager of Hunan fangshengtang Pharmaceutical Co., Ltd., chairman and general manager of Hunan Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Co., Ltd., chairman and general manager of Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Co., Ltd. He is currently the chairman of Hunan Kaishun Investment Consulting Co., Ltd., the executive director and general manager of Hunan Weibang new energy Co., Ltd., the supervisor of Hunan Baohua Environmental Protection Technology Co., Ltd., the chairman of Hunan Baohua environmental protection Co., Ltd., the executive director and general manager of Bisheng environmental protection Co., Ltd., Zhang Jia Jie Tourism Group Co.Ltd(000430) Baohua environmental protection Co., Ltd., the supervisor of Hunan Kexin Health Industry Group Co., Ltd, Chairman of Hunan Xiangya xileyuan health and elderly care management Co., Ltd., director of Shanghai Tongtian Biotechnology Co., Ltd., director of Hunan Baijun high tech Medical Investment Management Co., Ltd., and Hunan Fangsheng Huamei Medical Technology Co., Ltd
